---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-010148"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T01:46:30.088016+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics updates on GT-02287 Phase 1b trial for Parkinson's disease

## Summary
- Phase 1b trial of GT-02287 approved; dosing imminent in Australia, enrolling 15-20 patients with GBA1 or idiopathic PD.
- Prior healthy volunteer study showed 53% increase in GCase activity and confirmed safety/tolerability.
- Cash of $12M as of September 30, 2024, expected to fund operations through interim analysis in 2Q 2025.
- FDA pre-IND meeting found no significant regulatory hurdles; IND submission on track for Phase 2 planning in 2H 2025.
- Promotion of Gianluca Fuggetta to SVP Finance; company exploring licensing partners and financing options.

## SEC filing metadata
- accession: 0001104659-25-010148
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465925010148/0001104659-25-010148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465925010148/tm255679d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-010148
- JSON: https://secwatch.observer/filing/0001104659-25-010148.json
- Plain text: https://secwatch.observer/filing/0001104659-25-010148.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.